Arrhythmias & electrophysiology

Nonspecific Effects in Atrial Fibrillation Ablation: Insights From SHAM-PVI and Other Sham-Controlled Trials, Methodology Corner

JACC AdvPublished evaluation of sham-controlled cardiovascular trials

Authors' conclusion

These findings provide a practical framework for interpreting AF-burden endpoints and emphasize the importance of sham-controlled trial design in distinguishing lesion-specific therapeutic benefit from nonspecific procedural influences.

Study context

Population
Sham-controlled cardiovascular trials with subjective and objective endpoints; framework applied to atrial fibrillation (AF) ablation
Comparison
Within-arm change in the sham arm relative to the active arm
Outcome
Nonspecific fraction (ƒ) across renal denervation and percutaneous coronary intervention trials
Methodological detailssensitivity modeling
  • Sensitivity modeling

Main finding

As reported in the abstract

ƒ range

0.09 to 0.71

Further findings

AF burden in the sham arm of SHAM-PVI (continuous implantable loop recorder monitoring)

Reduction in AF burden in the sham arm
35.0 percentage-point
ƒ
ƒ≈0.58

Share of within-ablation AF-burden reduction reflecting nonspecific procedural effects (sensitivity modeling)

May reflect nonspecific procedural effects
25% to 70%
  • Lesion-specific AF-burden reduction estimated as (1-ƒ) × observed reduction

Original publication

Nonspecific Effects in Atrial Fibrillation Ablation: Insights From SHAM-PVI and Other Sham-Controlled Trials, Methodology Corner. JACC Adv. Published 20 August 2026. doi:10.1016/j.jacadv.2026.103130

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.